secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2022-09-22T23:59:59+00:00
Accession:  0000950170-22-018774
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux appoints Winston Kung to board; Stefan Heller resigns
-----------------------------------------------------------

- Winston Kung appointed as Class I director, term expiring at 2025 annual meeting, effective Sept 21, 2022.
- Stefan Heller resigned from board effective same day; not due to any disagreement with the company.
- Kung receives $40k annual cash retainer (board) + $4k (committee) and stock options: 30k shares (3-yr vest) and 9,375 shares (1-yr vest).
- Kung is CFO/COO at PMV Pharma; prior VP Business Development at Celgene and roles at Citigroup and Amgen.
- Changes effective immediately per press release dated September 22, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022018774/0000950170-22-018774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022018774/janx-20220921.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer